Green Cross seeking free supply of Peramir

Published: 2009-11-25 06:58:00

Updated: 2009-11-25 06:58:00

Green Cross Corporation is considering offering an investigational antiviral drug Peramivir intravenous (IV) for the treatment of certain adult and pediatric patients with confirmed or suspected H1N1 influenza infection who are admitted to a hospital.

Green Cross said Peramivir will be distributed to patients in limited amount upon doctor’s clinical judgment. The company is set to apply for ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.